|Galectin Therapeutics, Inc.|
4960 Peachtree Industrial Boulevard
United States - Map
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The companys lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase 1/2 clinical trials in Belgium as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
|Galectin Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 7; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. James C. Czirr ,
|Dr. Peter G. Traber M.D.,
Chief Exec. Officer, Pres, Chief Medical Officer and Director
|Mr. Jack W. Callicutt ,
Chief Financial Officer and Principal Accounting Officer
|Dr. Harold H. Shlevin Ph.D.,
Chief Operating Officer and Corp. Sec.
|Dr. Theodore D. Zucconi Ph.D.,
Director of Bus. Devel.
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|